Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nyse  >  Pfizer    PFE

PFIZER

(PFE)
  Report  
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector newsAnalyst Recommendations

Pfizer : to shut two manufacturing plants in India

share with twitter share with LinkedIn share with facebook
share via e-mail
0
01/09/2019 | 12:08pm EDT
FILE PHOTO: Logo of U.S. pharmaceutical corporation Pfizer Inc. is seen in Zurich

(Reuters) - U.S. drugmaker Pfizer Inc said on Wednesday it was shutting down two manufacturing plants in India that make generic injectables like penicillin as a response to falling demand.

Indian financial newspaper Business Standard reported https://www.business-standard.com/article/companies/pfizer-to-stop-manufacturing-operations-in-chennai-aurangabad-units-119010801430_1.html the news on Tuesday, saying over 1,700 employees would be impacted by the closure of the two factories in the states of Tamil Nadu and Maharashtra.

The factories employ nearly 6 percent of Pfizer's global manufacturing workforce.

"Pfizer has conducted a thorough evaluation of the ... sites in India and concluded that due to the very significant long term loss of product demand, manufacturing at these sites is not viable," the company said in an emailed statement.

Pfizer acquired the sites as part of its $15 billion (£11.7 billion) purchase of Hospira Inc in 2015, to boost its portfolio of generic injectable drugs and copies of biotech medicines.

The plant in Chennai makes generic injectable cephalosporin, penems and penicillin. The Maharashtra plant supplied the Chennai unit with certain products.

Both plants do not manufacture products for the India market, Pfizer said, adding that it is expanding operations in its Visakhapatnam facility in south India.

(The story corrects the third paragraph to show plants employ nearly 6 percent of manufacturing workforce, not total workforce)

(Reporting by Tamara Mathias in Bengaluru; Editing by Arun Koyyur)

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on PFIZER
01:11aPFIZER : Closes $10.6bn deal for array biopharma
AQ
06/17ARRAY BIOPHARMA : Pfizer makes $10.6 billion cancer bet in cash deal for Array B..
RE
06/17PFIZER : Description Statement of Changes in Beneficial Ownership
PU
06/17Business Highlights
AQ
06/17MARKET SNAPSHOT: Stocks Close Higher As Social Media, Real Estate Shares Lead
DJ
06/17MARKETS RIGHT NOW : Stocks climb, adding to recent gains
AQ
06/17PFIZER : to Buy Array BioPharma in $10.64 Billion Deal -- 4th Update
DJ
06/17PFIZER : Description Annual Report of Employee Stock Plans
PU
06/17PFIZER : bolsters cancer portfolio with $10.64bn deal for Array
AQ
06/17PFIZER : to acquire Array in $10.64bn deal
AQ
More news
Financials ($)
Sales 2019 53 351 M
EBIT 2019 19 750 M
Net income 2019 13 323 M
Debt 2019 26 335 M
Yield 2019 3,34%
P/E ratio 2019 17,84
P/E ratio 2020 16,29
EV / Sales 2019 4,97x
EV / Sales 2020 4,87x
Capitalization 239 B
Chart PFIZER
Duration : Period :
Pfizer Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends PFIZER
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 16
Average target price 45,6 $
Spread / Average Target 6,2%
EPS Revisions
Managers
NameTitle
Albert Bourla Director, Chief Executive & Operating Officer
Ian C. Read Executive Chairman
Frank A. D'Amelio Chief Financial Officer & EVP-Business Operations
Freda C. Lewis-Hall Chief Medical Officer & Executive Vice President
W. Don Cornwell Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
PFIZER-2.04%233 072
JOHNSON & JOHNSON8.55%348 981
ROCHE HOLDING LTD.13.11%227 848
NOVARTIS20.71%220 893
MERCK AND COMPANY9.02%206 641
ELI LILLY AND COMPANY-3.44%113 364